Skip to content

Do newborns with single episode of convulsions need continued treatment with phenobarbitone

EFFECT OF WITHHOLDING PHENOBARBITONE MAINTENANCE ON TREATMENT OF NEONATAL SEIZURES:A RANDOMIZED CONTROL TRIAL

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/11/003122
Enrollment
100
Registered
2012-11-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- newborns with seizures

Interventions

Intervention1: Effect of post seizure prophylaxis of phenobarbitone in neonatal seizures: a randomized control trial: control group:phenobarbitone comparator agent:Normal saline Intervention2: give ph

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.equal or more than 35 week gestation 2.equal or more than 2 kg 3.equal or less than 15days postnatal age

Exclusion criteria

Exclusion criteria: 1.Recurrence of seizure episode within 12 hrs of first loading dose of phenobarbital. 2.Major congenital malformations. 3.Hepatospleenomegaly(raising doubts of storage disease or intrauterine infections). 4.Suspected chromosomal abnormalities(based on facial dysmorphism and other phenotypic abnormalities)which itself are linked with cognitive and mental problems. 5.Very sick infans requiring assisted ventilation at admission.However,babies who get intubated after randomization will not be excluded.

Design outcomes

Primary

MeasureTime frame
To compare proportion of babies developing breakthrough seizures in next 5 days in groups receiving maintenance therapy of phenobarbitone(5 mg/kg/days) in two divided doses)versus who do not receive maintenance dose of phenobarbitone 12 hrs after giving its loading dose.Timepoint: 1.Breakthrough seizure within next 5 days of randomization 2.Till Six months of age: neurological and developmental evaluation.

Secondary

MeasureTime frame
To compare two groups with respect to: 1.Time to full oral feeding. 2.Duration of stay in hospital 3.EEG & MRI changes before discharge. 4.Neurodevelopmental status at discharge,3 & 6 months. 5.Seizure recurrence rate up to 6 months of age.Timepoint: same as above as mention in primary outcome time points

Countries

India

Contacts

Public ContactAMIT UPADHYAY

L.L.R.M COLLEGE,MEERUT

pranjali.saxena@gmail.com8090462403

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026